This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Effectiveness results
The intervention (chemotherapy plus G-CSF) group had a duration of nadir WBC of 8.4 days, whilst the control group (chemotherapy alone) had a corresponding figure of 10.8 days (p=0.006). Mean nadir in patients with a CD4 count >/=200 per mm3 was 1293 (+/-143) in the intervention group and 410 (+/-285) in the control groups, (p=0.009). When all patients with any CD4 count were considered, the difference was lower with p = 0.09. Mean duration of delays between cycles was 4 and 9 days for the intervention and control groups, respectively (p=0.01). The event rates for febrile neutropenia, number of culture-confirmed infections, the mean number of chemotherapy cycles, the proportion of patients who received full doses of chemotherapy, the complete response rates (69% and 67% for intervention and control, respectively), were comparable between groups. Moreover, the severity of infection in the control group was reported as higher (no additional details were given apart from almost all being bronco pulmonary infiltrates) than that for the intervention group. The mean number (SD) of toxicity-related days of hospitalisation was 6.4 (SD=9.1) for the intervention group versus 18.0 (13.2) for the control group (P= 0.003).
Measure of benefits used in the economic analysis
Toxicity avoided, as measured by decrease in mean duration (in days) of nadir white blood cell (WBC), mean number of chemotherapy cycles and mean duration of delays between cycles were the main benefit measures.
